

Befovacimab

Cat. No.:	HY-P99465
CAS No.:	2156634-62-5
Target:	Thrombin
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research ^[1] .
In Vitro	Befovacimab binds human TFPI with high affinity (<10 pM) via the K1 and K2 domains, inhibiting its interactions with both FXa and FVIIa and thus restoring their activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	In monkey plasma, Befovacimab exhibits an IC ₅₀ of 4.65 nM and 6.19 nM for free TFPI and diluted prothrombin time (dPT), respectively ^[1] . Befovacimab (5 and 20 mg/kg; intravenous and subcutaneous administration) dose-dependent decreases in TFPI concentration and clotting time in female cynomolgus monkeys in vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Maria Elisa Mancuso, et al. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis. *Haemophilia*. 2022 Sep;28(5):702-712.

[2]. Jian-Ming Gu, et al. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys. *AAPS J*. 2017 Jul;19(4):1186-1195.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA